Close Menu

Theradiag

Theradiag's Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant drug.

The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products. 

The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.

NEW YORK (GenomeWeb News) – Diagnostic firm Theradiag today announced a partnership with French organizations to develop diagnostic and theranostic tools for rheumatoid arthritis.

NEW YORK (GenomeWeb News) – French molecular diagnostics firm Theradiag announced Monday that its microRNA diagnostics subsidiary Prestizia has inked two deals to develop HIV/AIDS assays in collaboration with the French National Center for Scientific Research (CNRS).

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Theradiag this week announced several management changes in line with the strategic organization of the company into two divisions following last year's acquisition of microRNA technology firm Prestizia.

NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.